Texas Dermatology and Laser Specialists
Texas Dermatology and Laser Specialists
San Antonio, Texas, United States25 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 1 | 2026-10-07 | NCT07527923 | |
| A Study of Zasocitinib in Adults With Nonsegmental Vitiligo | Nonsegmental Vitiligo | Recruiting | Phase 2 | 2026-09-30 | NCT07108283 | |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | Abnormalities, Multiple, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ichthyosiform Erythroderma, Congenital, Infant, Newborn, Diseases, Netherton syndrome, Skin Abnormalities, Skin and Connective Tissue Diseases, hereditary disease, hereditary skin disorder, ichthyosis, keratosis, skin disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-28 | NCT07538583 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06143878 | |
| A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06095115 | |
| A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06934226 | |
| Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) | Plaque Psoriasis | Recruiting | Phase 3 | 2026-09-22 | NCT07116967 | |
| A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata | Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Phase 3 | 2026-09-18 | NCT06873945 | |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Neoplasms by Site, Skin and Connective Tissue Diseases, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 3 | 2026-09-16 | NCT06585410 | |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | NonSegmental Vitiligo | Recruiting | Phase 3 | 2026-09-14 | NCT06548360 | |
| A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata | Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Phase 3 | 2026-09-10 | NCT07733765 | |
| A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata | Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alopecia, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Phase 3 | 2026-09-08 | NCT05723198 | |
| A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, nutritional disorder, obesity disorder, overnutrition, psoriasis, skin disorder | Recruiting | Phase 4 | 2026-09-04 | NCT06857942 | |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis | Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Diseases, Papulosquamous, Skin Manifestations, Skin and Connective Tissue Diseases, exanthem, psoriasis, skin disorder | Recruiting | Phase 3 | 2026-09-03 | NCT06979453 | |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. | Moderate to Severe Genital Psoriasis | Active, not recruiting | Phase 3 | 2026-09-01 | NCT06611163 | |
| A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Active, not recruiting | Phase 3 | 2026-08-26 | NCT07029711 | |
| A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Enrolling by invitation | Phase 3 | 2026-07-30 | NCT05735483 | |
| A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 3 | 2026-07-30 | NCT05559359 | |
| An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin Abnormalities, Skin and Connective Tissue Diseases, epidermolysis bullosa, epidermolysis bullosa simplex, hereditary disease, hereditary skin disorder, skin disorder, vesiculobullous skin disease | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-09 | NCT06073132 | |
| A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. | Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Phase 3 | 2026-04-28 | NCT07029828 | |
| A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | NonSegmental Vitiligo | Active, not recruiting | Phase 3 | 2026-03-31 | NCT06113471 | |
| A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa | Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Corneal Injuries, Craniocerebral Trauma, Eye Injuries, Facial Injuries, Skin Abnormalities, Skin and Connective Tissue Diseases, connective tissue disorder, corneal disorder, epidermolysis bullosa, epidermolysis bullosa dystrophica, eye disorder, hereditary disease, hereditary skin disorder, injury, nervous system disorder, nervous system injury, recessive dystrophic epidermolysis bullosa, skin disorder, vesiculobullous skin disease | Recruiting | Phase 3 | 2026-03-12 | NCT07016750 | |
| Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata | Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Phase 3 | 2026-01-28 | NCT07133308 | |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | DNA Virus Infections, Infections, Skin Diseases, Viral, Skin and Connective Tissue Diseases, Tumor Virus Infections, common wart, human papilloma virus infection, skin disorder, skin disorder caused by infection, viral infectious disease | Recruiting | Phase 3 | 2026-01-21 | NCT07246590 | |
| Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Active, not recruiting | Phase 2 / Phase 3 | 2025-10-22 | NCT03898479 |